LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

PNC Financial Services Group Inc. lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 123.8% ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...